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Peripheral tolerance orchestrated by regulatory
T cells, dendritic cells (DCs), and mast cells (MCs)
has been studied in several models including skin
allograft tolerance. We now define a role for MCs in
controlling DC behavior (‘‘conditioning’’) to facilitate
tolerance. Under tolerant conditions, we show that
MCs mediated a marked increase in tumor necrosis
factor (TNFa)-dependent accumulation of graft-
derived DCs in the dLN compared to nontolerant
conditions. This increase of DCs in the dLN is due
to the local production of granulocyte macrophage
colony-stimulating factor (GM-CSF) by MCs that
induces a survival advantage of graft-derived DCs.
DCs that migrated to the dLN from the tolerant allo-
graft were tolerogenic; i.e., they dominantly suppress
T cell responses and control regional immunity. This
study underscores the importance of MCs in con-
ditioning DCs to mediate peripheral tolerance and
shows a functional impact of peripherally produced
TNFa and GM-CSF on the migration and function of
tolerogenic DCs.
INTRODUCTION
Mast cells (MCs) populate the mucosa and skin, representing
one of the cells earliest to recognize the breach of the host by
an invading pathogen. As such, the role of MCs in early innate
responses has been well studied (Bischoff and Kra¨mer, 2007;
Metz et al., 2008). However, we now know that the early innate
response ‘‘conditions’’ the ensuing adaptive response both in
a qualitative and quantitative manner to generate appropriate
acquired immune responses to control infection. In this context,
one of the key immunoregulatory facets of MC function in regu-
lating the development of adaptive immunity is their capacity to
regulate the migration of dendritic cells (DCs) from tissue to
secondary lymphoid organ. It is well established by the work of
Galli and coworkers that tumor necrosis factor a (TNFa) pro-
duced by MCs mediates DC migration under inflammatory con-
ditions and in its absence the magnitude of inflammation is550 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.ameliorated (Suto et al., 2006). Previously published studies
from our lab have shown that MCs are required in a model of
skin allograft tolerance mediated by Foxp3+ regulatory T cells
(Treg) cells (Lu et al., 2006). It has recently become apparent
that, like for inflammation, the trafficking of DCs from tissue to
regional secondary lymphoid organs is critical to maintain toler-
ance as well. It is through the control of DC migration, and the
conditioning of tolerogenic DC functions, that MC may exert a
profound effect on the maintenance of peripheral tolerance
(Dudeck et al., 2011; Ochando et al., 2006).
In this study, we show MCs and MC-derived factors control
DC function that is ultimately required for the maintenance of
acquired peripheral tolerance. Under inflammatory conditions,
MCs are critical for DC migration (Shelburne et al., 2009; Suto
et al., 2006). This present study evaluated whether MC also con-
trolled DC migration under tolerogenic conditions and whether
this was functionally important in maintaining tolerance. As in
inflammatory conditions, we show that DCs from tolerant allo-
grafts also migrate in a TNFa-dependent fashion. Upon analysis
of the migration of DCs from tolerant tissue, we observed that
there was a 3- to 6-fold increased accumulation of DCs in the
dLN when compared to the dLN proximal to a syngeneic graft.
The migrated DCs were able to dominantly suppress T cell
responses even though outnumbered by immune stimulatory
DCs in the same dLN. Further studies indicated that the in-
creased accumulation of tolerogenic DCs in the dLN was due
to their extended life span. The observation of very high amounts
of GM-CSF in allografts of tolerized mice was confirmed to be
the mechanism for the enhanced graft survival. Data suggest
that MC-derived GM-CSF conditioned the graft-derived tolero-
genic DCs by inducing a transcriptional survival program leading
to an accumulation in the dLN over time. This finding is shows
that MCs play a pivotal role in the conditioning of DCs to mediate
tolerance.
RESULTS
DCs Are Critical for the Maintenance of Skin Graft
Tolerance
The allograft tolerance induced by donor specific transfusion
(DST) and aCD40L is an active process of suppression mediated
by the expansion and differentiation of regulatory T (Treg) cells
(Quezadaetal., 2003).SustainingactiveTregcell function tomain-
tain the tolerant state may require DCs to trigger antigen-specific
Figure 1. DC Migration Is Required for Establishment of Tolerance
(A) WT or Itgax-DTR mice were grafted with B6 (syngeneic, syn), F1 skin (rejecting, rej), or F1 skin (tolerant, tol). The tolerant group was pretreated with donor-
specific transfusion (DST) and aCD40L. At day 7 postgrafting, DCs were depleted locally by intragraft injection with 50 ng of Diphtheria toxin (DT).
(B) WT mice were grafted as in (A) and DC migration was blocked by intragraft injection of 1 mg of sTNFR-Ig or isotype control at day 1, 3, 5 and 7 post-grafting.
Grafts were FITC painted at day 10 post-grafting and 18h later the dLN were analyzed for FITC+ graft-derived DCs.
(C) Mice were grafted as described in (A) and treated with the sTNFR-Ig as in (B). All KitW-sh mice were tolerized with DST and aCD40L. Data are presented as
mean ± SEM.
(D) FITC painting (topical application), Dextran-A647 or DQ-OVA (intragraft injections) were compared. The fold change of graft derived DC over control
(syngeneic) is depicted.
(E and F) Grafts were collected and weighted before analysis. Relative numbers (E) of total retrieved cells or absolute numbers (F) of DCs per mg graft tissue are
shown. Dots in (D)–(F) represent individual mice pooled from at least two independent experiments.
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to whether DCs are critical for sustaining allograft tolerance,
CD11c-diphtheria toxin receptor mice (Itgax-DTR) were grafted
with allogeneic or syngeneic skins. These mice express the DTR
under the CD11c promoter and administration of diphtheria toxin
(DT) selectively kills cells expressing CD11c (Jung et al., 2002),
includingDCs. Local treatment of themicewithDTat day 10post-
grafting resulted in rapid rejection of the allograft in pretolerized
mice (Figure 1A). Thus, DCs are required for the maintenance of
tolerance.
DC Migration and the Role of TNFa in Sustaining
Allograft Tolerance
In a vascularized allograft model, it has been shown that the
migration of plasmacytoid DCs to the regional LN was essential
to sustain peripheral tolerance (Ochando et al., 2006). Figure 1A
implicated involvement of DCs in the maintenance of skin allo-
graft tolerance and thus, the importance of DC migration was
addressed. To intervene in DC migration, we neutralized TNFa
in vivo using soluble TNF receptor-Ig (sTNFR-Ig). Under inflam-
matory conditions, it has been established that MC-derivedTNFa is required for optimal migration of DCs to the dLN and
T cell priming (Shelburne et al., 2009; Suto et al., 2006) and we
reasoned it would be similarly true under tolerant conditions.
DC migration was measured by painting of skin grafts with
FITC at day 10 postgrafting. Graft-derived DCs (CD11c+MHC-II+
FITC+ DCs) in the regional LN of mice bearing a syngeneic graft,
a tolerant allograft, or an allograft in the process of rejection were
enumerated at 18 hr after application of FITC in combination with
sTNFR-Ig. Administration of sTNFR-Ig universally ablated DC
migration fromsyngeneic, allogeneic, and tolerant allografts (Fig-
ure 1B). To evaluate whether TNF blockade exerted a functional
impact on graft rejection or tolerance, we treated mice with
sTNFR-Ig and monitored graft survival. TNF blockade induced
acute graft rejection in pre-tolerized mice that normally would
have accepted the allograft (Figure 1C). Also, treatment at day
30 postgrafting with sTNFR-Ig led to a break in established toler-
ance (Figure S1A available online). Taken together, these data
are consistent with the hypothesis that TNFa-driven DC migra-
tion may be critical to sustain tolerance.
When analyzing the impact of TNFa blockade on DC migra-
tion, it was observed that the number of graft-derived DCsImmunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc. 551
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neic or rejecting conditions (Figure 1D, FITC paint). Trivial expla-
nations for this as FITC drainage to the LN or systemic labeling of
DCs was discounted by the fact that TNFa blockade eliminated
the appearance of FITC+ DCs in the dLN in all cases (Figure 1B).
The possibility of antigen transfer from the migrating DCs to the
resident LN DCs was excluded on the basis of the fact that the
MFI of the graft-derived DCs was similar to the MFI in the dLN
(Figure S1B). Transfer of FITC as a result of representation of
migrating DCs is not possible without a reduction in MFI. Finally,
the number of DCs in tolerant versus syngeneic in the graft
(Figures 1E and 1F) or in the dLN (data not shown) were not
grossly different, and actually the rejecting group showed an
increase in both relative and absolute numbers of local DCs
compared to those in syngeneic and tolerant. Therefore, the
number of DCs in tolerant grafts and their migration does not
account for the substantial increase of graft derived DCs
observed in the regional LN. The increased DC accumulation
could be verified by alternative methods of tracking DC migra-
tion. Both intragraft injection of Dextran-A647 and DQ-OVA
gave a similar result in the fold change over syngeneic controls,
although the absolute number of positive DC was reduced (Fig-
ure 1D). This also shows that the uptake (dextran-A647) and pro-
cessing (DQ-OVA) of antigen by graft-derived DCs were not
impaired. Additional data to explain the basis for increased accu-
mulation of DCs in tolerant mice will be presented below.
Loss of Graft Tolerance andDCMigration inKitW-shMice
The data presented show that DC migration from tolerant allo-
grafts is TNFa dependent, and it has been well established that
membrane-bound, MC-derived TNFa triggers DC migration
during inflammation (Suto et al., 2006). Increased MC numbers
have been reported in tolerant allografts (de Vries et al., 2009;
Lu et al., 2006), and MC of tolerant, but also syngeneic and
rejecting grafts, express membrane-bound TNFa (Figure S1C).
Because sTNFR-Ig blocked DC migration (Figure 1B) from
tolerant allografts and the MCs expressed membrane-bound
TNFa needed for DC migration, we predicted that the absence
of MC in pretolerized mice would prohibit the persistence of
a tolerant allograft and impair DCmigration. As published, preto-
lerized MC-deficient (KitW-sh) mice begin to lose their grafts at
20 days (Lu et al., 2006) (Figure 1C). Reconstitution with WT
bone marrow-derived MC (BMMCs) can partially restore this
defect. For tracking of DC migration, normal and KitW-sh mice
grafting was followed by FITC painting at day 10. After 18 hr,
the dLNs were analyzed for the presence of graft-derived
FITC+ DCs by flow cytometry (Figures 2A and 2B) and histology
(Figure 2D). Migration of DCs to the dLN in tolerized KitW-sh mice
was profoundly reduced when compared to migration observed
in tolerized WT mice (Figure 2B). This reduction could be re-
stored by reconstitution of KitW-sh mice with WT BMMCs to
about 70% of what is seen in pre-tolerized C57Bl/6 mice (Fig-
ure 2B). The presented data show that there is a MC-dependent,
TNFa-dependent increase in graft-derived DCs in the dLNs of
tolerant allografts which is critical to maintain allograft survival.
To generate a more complete profile of DC migration over
a longer time period, we monitored graft-derived DC migration
to the regional LN over 48 hr (Figure 2C). During the first 12 hr,
accumulation of graft-derived DCs was similar between tolerant,552 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.syngeneic, and rejecting mice, suggesting that the initial rate of
migration is not different between groups. However, after
12 hr, a decline was observed in the number of graft-derived
DCs in the syngeneic and rejecting groups whereas the pretoler-
ized mice showed a further increase at 18 hr, which persisted at
24 hr. This confirmed the previous shown data (Figures 1B, 2A,
and 2B) that enhanced DC accumulation is observed only under
tolerant conditions. Alternatively, KitW-shmice showed a delayed
DC migration, confirming previous studies (Suto et al., 2006).
These results show that the initial migratory response of the
DCs to the regional LN from all graft types is similar for up to
12 hr. After 12 hr, and up to 48 hr (p48h = 0.0169 compared to
syngeneic), the DCs from the tolerant graft appear to accumulate
and persist, whereas the DCs from the rejecting and the synge-
neic grafts do not. In summary, we showed that there is an
increase in both relative and absolute numbers of graft-derived
DCs in the dLN under tolerant conditions independent of antigen
drainage, antigen transfer, or a higher initial number of DCs in the
graft. Further studies addressing the mechanisms of increased
DC accumulation in tolerance will be presented below.
Differences in Phenotypes of Migrating Graft-Derived
DC Subsets from Tolerant versus Rejecting or
Syngeneic Grafts
We performed studies to evaluate the origins and phenotypes of
the graft-derived DCs. To determine if the migrating DCs were of
donor or host origin, we grafted Ly5.2 mice with Ly5.1 grafts.
After FITC painting, we analyzed the dLN for the presence of
either Ly5.1 or Ly5.2 DCs. At 18 hr after FITC painting, virtually
no Ly5.1 DCs were observed, suggesting that the accumulating
DCs are host derived (Figure S2). Additionally, no differences in
the surface marker expression of MHC-II, CD80, CD86, and
CD40 were observed (data not shown).
The six major populations of migratory DCs present in the skin
dLN were quantified by phenotypic analysis of surface markers.
The broad differentiation was based on expression of CD8a, in
which CD8a+ are from lymphoid origin and the CD8a are
myeloid. Differentiation of Langerhans cells (LHCs) was deter-
mined on the basis of the expression of CD326 and CD103 in
which the CD103+ DCs are ‘‘professional’’ CD8 T cell presenters
(del Rio et al., 2007). Analysis of DC subsets in the dLN of tolerant
mice showed that the CD103+ DCs were greatly diminished
under tolerizing conditions (Figure 2E). Interestingly, the lym-
phoid DC subset (CD8a+CD11b), known to be able to cross-
present antigen, was increased. In contrast, the myeloid sub-
population (CD8aCD11b+) showed a reduction (Figure 2E).
No Gr1+CD11b+ ‘‘myeloid suppressor’’ DCs (<0.5%) were found
within themigrating population of DCs (data not shown). Further-
more, no substantive differences were found in the dermal DC,
LHC, or plasmacytoid DC at this time point. Altogether, this
results shows that under tolerant conditions, there is a skewing
of the early migrating DCs toward the lymphoid subsets at the
expense of both myeloid and CD103+ DCs.
Graft-Derived DCs but Not Other DCs in the Graft dLN
of Tolerized Mice Are Dominantly Suppressive
Central to the ability of the DCs to maintain tolerance is their
capacity to functionally silence alloreactivity. First, the ability of
the graft-derived DCs to act as proficient APCs to elicit T cell
Figure 2. Graft-Derived DCs Accumulate in the Graft dLN under Tolerant Conditions
(A and B) Grafts of WT or KitW-sh mice were FITC painted at day 10 postgrafting. The graft dLN were collected at 18h later and analyzed for graft derived
FITC+ DCs.
(B) Quantification of the total number of FITC+ DCs in the dLN, with every dot representing an individual mouse. Non-dLNs were analyzed and less than 1% of the
DCs were FITC positive (data not shown).
(C) Kinetics of graft derived DC accumulation under syngeneic, rejecting and tolerant (WT and KitW-sh) conditions. At day 10 FITC was applied to graft and at
different times after FITC painting dLN were analyzed for the presence of FITC+ graft derived DCs.
(D) Histology of the dLN at 18h post FITC painting. Graft derived DCs are FITC+CD11c+.
(E) Composition of the migrating DCs at 12 hr post-FITC painting of day 10 grafts (mean ± SEM).
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Mast Cells Condition Tolerogenic Dendritic Cellsresponses was evaluated. Graft-derived Ly5.1+DCs (by sorting
MHCIIhighCD11c+FITC+ cells) were pulsed with ISQ (OVA pep-
tide recognized by OT-II transgenic T cells) and cocultured
with CFSE-labeled OVA-specific Ly5.2+ OT-II transgenicT cells (OTII T cells). As expected, OTII T cell proliferation was
observed when syngeneic and rejecting graft-derived DCs
were used (Figure 3A). However, when graft-derived DCs from
tolerized mice (Tolerant (graft)) were used greatly reducedImmunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc. 553
Figure 3. Graft-Derived DCs Are Dominantly Suppressive, whereas Non-Graft-Derived DCs within the Same dLN Still Can Activate T Cells
(A) Graft-derived Ly5.1+FITC+ DCs (‘‘Syngeneic,’’ ‘‘Rejecting,’’ and ‘‘Tolerant (graft)’’) were sorted and ex vivo pulsed with OVA-peptide (ISQ). Alternatively, DCs
within the same dLN that were derived from FITC painting the foot were isolated (‘‘Tolerant (foot)’’). The non-graft-derived DCs were labeled by FITC painting of
the front footpad of the allografted and tolerized mice. Subsequently, the ISQ-pulsed DCs were cocultured for 4 days at different ratios with CFSE labeled OVA-
specific TCR transgenic OTII Ly5.2+ T cells. After 4 days, CFSE dye dilution was analyzed within the CD4+Ly5.2+ population. In order to address whether the graft-
derived DCs were dominantly suppressive, all dLN DCs without FITC painting (‘‘Tolerant (whole LN)’’) were pulsed with ISQ.
(B) Mice were tolerized and at day 10 post grafting and locally treated by either intragraft or front footpad injection of OVA-Alum. This treatment would ensure OVA
being processed and presented by either the graft-derived DCs or non-graft-derived DCs. Like in (A), for both treatments axillary and inguinal were used as dLNs.
Whole dLNs were collected and the purified DCs were cultured as in (A). Shown are representative histograms of four independent experiments with 3 or 4 mice
per group.
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are ineffective APCs.
Second, the ability of DCs derived from a tolerant allograft to
suppress the proliferation of T cells when in the presence of other
(non-FITC+) APCs was assessed. As such, in lieu of sorting graft-
derived DCs, whole dLN DCs (containing both graft-derived DCs
and LN-resident DCs) from tolerized mice without FITC painting
were used as a source of APCs. Suppression was observed in
the LN draining the tolerant allograft (Figure 3A, tolerant [whole
LN]). As expected, DCs in the dLN from mice with syngeneic
grafts or rejecting allografts showed robust proliferation (Fig-
ure S3). Therefore, in a pool of both immune stimulatoryand
tolerogenic DC, suppression is dominant in this model.
Third, we determined whether the coexistence within the dLN
of tolerogenic DCs and other DCs permanently ablated APC554 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.function of all DCs within that LN. The axillary and inguinal LNs
not only drain the graft but also other parts of the skin, including
the forelegs. One group of pretolerized mice received FITC
painting on the front footpads, which allowed the isolation of
a population of FITC+ DCs from a LN that also contained popula-
tions of tolerogenic DCs from the nearby tolerant allograft. FITC+
DCs (derived from the front footpads) were purified by cell sort-
ing, pulsed with ISQ, and cocultured with OT-II T cells. Interest-
ingly, the FITC+ DCs derived from outside the graft, but within the
samedLN, showed robust proliferation ofOT-II T cells (Figure 3A;
tolerant [foot]). This demonstrates that within the same dLN, the
presence of tolerogenic DCs does not permanently incapacitate
the APC activities of other DCs present in the LN.
A final verification that DCs are imprinted differentially in
a tolerant site versus a nontolerant site was derived from the
Figure 4. Graft-Derived Tolerogenic DCs Show Enhanced Survival
(A) At day 10 after receipt of the skin graft, local application of FITC (pulse) was followed by intragraft injection of sTNFR-Ig 3h later to block DC migration. At
different time points after FITC painting and sTNFR-Ig blockade, dLNswere collected. The DCs thatmigrated during the initial 3 hr were quantified (chase). Pooled
data from three independent experiments are shown.
(B and C) Because at 12 hr post-FITC painting a split was observed in graft-derived DC accumulation (Figure 2B), DCs were collected at this time point and
analyzed for survival by means of MitoTracker (B) and quantified on the basis of the percentage of MitoTracker+ cells (C). Pooled data from thtrr independent
experiments with every dot represents a single mouse.
(D and E) Grafts were collected, weighted, and incubated in plain HBSS. Supernatant was collected and analyzed for the presence of TNFa (D) andGM-CSF (E) by
ELISA. Pooled data from three independent experiments presented as mean ± SD.
(F) Skin grafts were stained with GM-CSF antibody (green) and costained with CD11c (red) for DCs and CD117 (blue) for MCs. To confirm specificity of the
antibody, we either incubated slides with an isotype control or preincubated them with unlabeled GM-CSF antibody of the same clone (‘‘cold GM-CSF’’).
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either the footpad (nontolerant site; ‘‘OVA-Footpad’’) or in a
tolerant allograft (tolerant site; OVA-Graft) and whole dLN DCs
were purified and cocultured with CFSE-labeled OT-II T cells.
When OVA was processed by DCs in vivo at a location outside
the transplant, robust proliferation was observed (red histo-
grams). However, when OVA was processed by DCs in the
tolerant, allogeneic skin graft, T cell proliferation was suppressed
(blue histograms). Thus, the functional status of tissue-derived
DCswithin the regional LN is imprinted by the site of tissue origin.
Graft-Derived DCs of Tolerized Mice Show Increased
Survival
The enhanced survival of tolerogenic DCs in the dLNwas consid-
ered a potential mechanism for the increased numbers of DCs in
the dLN of tolerant allografts. In order to address this, we per-
formed an in vivo pulse chase experiment by first FITC paintingthe graft and after 3 hr blocking migration by an intragraft injec-
tion of sTNFR-Ig. We have shown that this blocks all DC migra-
tion (Figure 1B). Therefore, only DCs thatmigrated during the first
3 hr after topical application of FITC would be reaching the graft
dLN. Accumulation of FITC+ DCs was still observed with a peak
at 12 hr under tolerant conditions whereas both syngeneic and
rejecting showed the highest number of graft-derived DCs in
the dLN at 9 hr after FITC painting (Figure 4A). However, a steep
decline was observed in all groups, most likely because TNFa is
also a survival factor for LHCs and DCs (Koch et al., 1990; Lude-
wig et al., 1995). Nonetheless, the number of graft-derived DCs
under tolerant conditions in the dLN was still increased. In con-
clusion, this suggests that graft-derived, tolerogenic DCs accu-
mulate in the dLN as a result of enhanced persistence.
Studies were performed to address whether this persistence
of DCs in the dLN of tolerant allografts was due to enhanced
survival. Graft-derived DCs were analyzed at 12 hr after FITCImmunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc. 555
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DCs was observed in rejecting and syngeneic conditions com-
pared to pretolerized mice (Figure 2C). The graft-derived DCs
from tolerized mice showed a higher percentage of viable cells
as shown by the use of MitoTracker, a dye that stains active
mitochondria (Figure 4B). Within the live gate, 10% of the
graft-derived DCs in the syngeneic showed to be MitoTracker
positive, meaning that 90% of the DCs were in the process of
undergoing apoptosis. In contrast, under tolerant conditions this
was 25% (Figure 4C). This result was confirmed by AnnexinV
staining. The relative change of AnnexinV versus MitoTracker
compared to syngeneic was 0.97 versus 1.07 for rejecting and
2.48 versus 3.31 for tolerant. Both MitoTracker and AnnexinV
staining suggest that there is a survival advantage of DCs
migrating from the immunosuppressive environment of the
tolerant graft, leading to a regional accumulation of DCs in the
dLN of the accepted allograft over time.
GM-CSF, a DC Survival Factor, Is Abundantly Present
within Tolerant Allogeneic Skin Grafts
The prior findings suggested that the cytokine environment of
the tolerant allograft might condition the DCs with enhanced
longevity. As such, differences in the cytokine milieu among
syngeneic, rejecting, and tolerant allografts were investigated
with regard to known survival factors for DCs. TNFa clearly
showed an impact on the survival of DCs in general (Figure 4A);
however, the local concentration was similar between the three
different groups (Figure 4D). Another survival factor for DCs is
GM-CSF. Luminex as well as ELISA analysis of GM-CSF in the
grafts showed markedly increased concentration in tolerant
allografts (Figure 4E). Staining of day 10 grafts showed a distinct
pattern ofGM-CSFonly in the tolerant graft (Figure 4F). This could
be blocked by preincubation of unlabeled GM-CSF antibody
(cold GM-CSF). The observed widespread and not clearly cell-
associated staining pattern is most likely caused by the binding
of GM-CSF to extracellular heparin containing proteoglycans,
which is required for optimal function of this cytokine (Alvarez-
Silva and Borojevic, 1996; Modrowski et al., 1998). Considering
that we observed changes in the subsets of the migrating DCs
(Figure 2E), a possible explanation could be that the subsets
had a different sensitivity to GM-CSF, giving survival advantage
to one but not the other subsets. We therefore tested purified
splenic DCs for potential subset-specific survival in response to
GM-CSF. Interestingly, we found that CD11bCD8a+ DCs accu-
mulated over time at the expense of both CD11b+CD8a and
CD103+ DCs. However, this was independent of GM-CSF
because a similar pattern was found in the absence of GM-CSF
(Figure S4). The results further strengthened the hypothesis that
the accumulation of tolerogenic DCs in the dLN was due to
a survival advantage when compared to syngeneic or rejecting
conditions and that GM-CSF potentially could provide this
survival signal.
GM-CSF Is Necessary for Graft Tolerance
GM-CSF has been repeatedly shown to be involved in the differ-
entiation and survival of DCs in vitro and in vivo (Sallusto and
Lanzavecchia, 1994). High amounts of GM-CSF were observed
only under tolerant conditions (Figures 4E and 4F), yet the neces-
sity for graft tolerance was not yet clear. In the first experiment,556 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.we therefore supplemented GM-CSF by four intragraft injections
during the first week after grafting in mice with either syngeneic
or allogeneic (rejecting) grafts. Supplementing GM-CSF even
for this brief period led to a significant shift (p = 0.011) in graft
survival without any treatment prior to grafting (Figure 5A). Con-
versely, blocking GM-CSF locally with the GM-CSF antibody in
either syngeneic or allogeneic (tolerant) grafts during the first
week after grafting induced rapid rejection of the tolerant graft
in 80% of the mice before day 25 (Figure 5B). The introduction
of GM-CSF as well as antibody treatment had no impact on graft
survival in syngeneic controls.
In addition, we found that the majority of pretolerized
GM-CSF-deficient (Csf2/) mice acutely rejected the allograft
before day 20 postgrafting (Figure 5C), whereas tolerized WT
mice normally accept the allograft for over 80 days. To exclude
a possible impact of the absence of GM-CSF on the number of
MCs, we tested several locations known to harbor MCs. This
revealed that Csf2/ mice have normal numbers of MC in all
tested tissues (Figure S5). Thus, the observed rejection in these
mice is not due to a reduction in MCs. In summary, we showed
that GM-CSF is indispensible for graft tolerance.
Graft-Derived Tolerogenic DCs Show a GM-CSF-
Dependent Upregulation of Antiapoptotic Molecules
It is known that the Csf2/ mice have 20% reduction in the
overall number of DCs (Kingston et al., 2009; Ni and O’Neill,
2001) and that GM-CSF induces a survival program in DCs pro-
tecting them from apoptosis (Chen et al., 2007). To address
whether GM-CSF impacted survival of DCs in vivo, we sorted
graft-derived DCs from the dLN. Genes known to be involved
in survival were analyzed by RT-PCR. Downregulation of the
proapoptotic BAD and upregulation of the antiapoptotic genes
Bcl2 and BclXL were observed in graft-derived DCs of tolerized
mice compared to DCs derived from rejecting allogeneic or syn-
geneic grafts (Figure 5D). Interestingly, Spi-6, known to protect
against Gzb-mediated killing, was also upregulated albeit
modestly. The caspase pathway does not seem to be affected.
Altogether, it seems that GM-CSF renders DCs less sensitive
to apoptosis by nutrient and growth factor deprivation and
provides some protection against GzB-mediated killing.
MCs Can Produce Large Amounts of GM-CSF
and Sustain DC Survival In Vitro
MCs can produce GM-CSF in response to activation by various
mechanisms, among which is IgE opsonization. This leads to
maturation and activation without degranulation as long as the
IgE-specific antigen is not present. However, the pool of IgE in
both mouse and man is heterogeneous and each clone can
induce a different response when binding to the FcεRI on MCs
(Kitaura et al., 2003). Additionally, IL-33 has been shown to
mature human MCs without degranulation (Allakhverdi et al.,
2007), inducing the production of a variety of immunological
mediators includingGM-CSF.We therefore first wanted to deter-
mine whether BMMCs could produce GM-CSF in response to
DNP-specific IgE (clone A3B1) and IL-33 as a positive control.
Normal ‘‘resting’’ BMMCs produced very small amounts of
GM-CSF, which increased 8-fold by the addition of IL33. How-
ever, activation with IgE induced an almost 20-fold increase
compared toWT controls (Figure 6A). As expected, IgE activated
Figure 5. GM-CSF Is Required for Tolerance by Inducing Prosurvival Genes in Graft Derived DCs
(A) Recombinant GM-CSF (50 ml; 800 ng/ml) was injected locally in the graft during the first week after grafting (days 1, 3, 5, and 7) to mice that received either B6
(syngeneic) or F1 (rejecting) skin graft.
(B) GM-CSF (50 ml anti-GMSCF; 10 mg/ml) was blocked locally in syngeneic and tolerized mice at days 1, 3, 5, and 7 and graft survival monitored.
(C) WT or Csf2/mice were grafted with syngeneic (B6) or allogeneic (F1) skins and/or tolerized with aCD40L plus DST. Graft rejection was followed for 60 days
after grafting.
(D) Graft-derived DCs were purified by sorting and analyzed for genes involved in apoptosis and survival by RT-PCR. For clarity labeling shows which major
pathway of apoptosis is affected, and whether the gene is pro- or antiapoptotic. Shown is one of two experiments with similar results.
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CSF. Staining of the IgE-activated and subsequently monensin-
treated BMMCs showed a distinct intracellular staining of
GM-CSF (Figure 6B). This shows that MCs when activated can
produce copious amounts of GM-CSF in vitro.
To directly assess whether MC can promote DC survival, we
created cocultures of BMMCs and splenic DCs; however, the
coculture led to the release of the granular content of the MCs
and negatively impacted the viability of the DC. Therefore, DC
culture media was conditioned by growing BMMCs for 24 hr in
the absence or presence of IgE for activation. Normal DC culture
conditions included theadditionofGM-CSF (positivecontrol) and
showed a gradual decline of viability with30% survival at 72 hr
from MitoTracker staining. In the absence of GM-CSF this was
10% (Figure 6C). BMMCs without stimulation showed a similar
trend as the negative control as did IgE activated BMMCs from
the Csf2/ mice. However, when supernatants of WT BMMCs
activated with IgE were used, an enhanced survival of the DCs
was observed compared to no GM-CSF (Figure 6C). Similar
survival data was obtained by microscopic analysis of the DCs
based on trypan blue exclusion (Figure S6). This shows that
MCs are indeed capable of producing a sufficient amount of bio-
logically active GM-CSF to prolong DC survival, at least in vitro.
MC-Derived GM-CSF Is Needed for Graft Tolerance
The next question we addressed is whether MC derived GM-
CSF is important for the establishment of graft tolerance byincreasing the resistance to apoptosis of graft-derived DCs
in vivo. To implicate MC derived GM-CSF, we locally reconsti-
tuted KitW-sh mice with either WT or Csf2/ BMMCs. After
8-10 weeks the mice were tolerized and grafted with allogeneic
skin. Control B6 mice were age matched and showed a nor-
mal pattern of rejection (allogeneic) or acceptance (syngeneic,
tolerant allogeneic). KitW-sh mice reconstituted with WT BMMCs
showed a gradual loss of tolerance (Figure 7A). However, 8 out of
10 KitW-sh mice receiving the Csf2/ MC rejected the grafts
before day 30. Surprisingly, Csf2/ MC reconstituted mice
rejected their grafts faster than non-reconstituted KitW-sh, sug-
gesting that these MC produce other mediators besides GM-
CSF that may be detrimental to graft survival in the absence of
GM-CSF.
MC-Derived GM-CSF Increased Longevity of Graft-
Derived DCs
Finally, we wanted to address whether DC survival was
altered when GM-CSF was lacking in the MC compartment
only. KitW-sh mice were reconstituted with either WT or Csf2/
BMMCs, tolerized, and grafted. At day 10 postgrafting, FITC
painting was applied and 12 hr later the graft dLNs were
collected and analyzed for the number of graft-derived FITC+
DCs and their viability by means of flow cytometry. Reconstitu-
tion withWTMCs did not restore the survival of DCs to the extent
of WT mice, mean of 5.8% ± 1.7% versus 14.9% ± 4.1%,
respectively, probably because of a lower density of MCs,Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc. 557
Figure 6. In Vitro-Cultured MCs Can Produce Large Amounts of Functional GM-CSF when Activated
(A) GM-CSF production by BMMCs from either WT or Csf2/mice after stimulation with nothing, 1 mg/ml of DNP-IgE, or 10 ng/ml recombinant IL-33 for 24 hr.
(B) Confocal images of DNP-IgE stimulatedMCs. MCs were treated for 12 hr with DNP-IgE and subsequently for 2 hr in the presence of monensin for intracellular
accumulation of GM-CSF (green). Surface staining was done with cKit (blue) and nuclear staining with Hoechst (pink). Pictures were recorded at 633 magni-
fication.
(C) Supernatant of (A) was used for maintaining bead-purified splenic DCs. For 72 hr, DCs were monitored for survival by flow cytometry (MitoTracker+). As
a positive control, complete RPMI was supplemented with 20 ng/ml GM-CSF (TCM+GMCSF). For negative controls, complete RPMI or conditioned media from
IgE stimulated Csf2/ MCs was used. Data presented as mean ± SEM are pooled from four independent experiments and had duplicates within each
experiment.
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reconstituted mice compared toWTmice. However, the Csf2/
MC reconstituted KitW-sh mice showed a significant decrease of
DC survival compared to WT MC reconstituted KitW-sh mice
(mean of 5.8% ± 1.7% versus 2.0% ± 0.7% respectively; p =
0.022) even though the reconstitution efficiency was the same
between these two groups (Figure S7B). It should be noted
that the total number of cells recovered in theCsf2/MC recon-
stituted mice was lower and thus the total number of recovered
FITC+ DCs was also reduced in these mice, this was reflected in
the absolute number of MitoTracker+ DC (Figure 7C). Together,
these results show that MC-derived GM-CSF has an important
role in the survival of graft-derived DCs and that the increased
resistance to apoptosis of graft-derived DCs in tolerized mice
is required for the establishment of graft tolerance.
DISCUSSION
The findings presented in this study show that MC are indispens-
able in conditioning DCs to mediate tolerance. First, we show
that the MC-dependent, TNFa-dependent migration of DCs
from the tolerant allograft to the dLN is required for the mainte-
nance of tolerance. We have not documented that MC-derived
TNFa is critical in our studies, but prior studies have clearly558 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.demonstrated MC-derived TNFa controls DC migration (Shel-
burne et al., 2009; Suto et al., 2006). Second, DCs in the dLN
of a tolerant allograft accumulate in a MC-dependent process.
Third, the DCs from tolerant allografts, but not DCs from a synge-
neic graft, are tolerogenic, i.e., incapable of inducing T cell prolif-
eration. Furthermore, the graft-derived DCs are dominantly
suppressive even though DCs that present in the same dLN
are still able to induce T cell proliferation when tested indepen-
dently. Fourth, production of GM-CSF from MCs is critical for
graft tolerance and conditions the enhanced survival of DCs in
tolerant allografts, which accounts for their increased accumula-
tion in the dLN.
Numerous lines of evidence presented suggest that DCmigra-
tion is critical for maintenance of graft tolerance. DT-mediated
depletion of DCs in our model elicited a breakdown in graft toler-
ance, establishing the involvement of DCs after the initial induc-
tion of tolerance with DST and aCD154. This suggests that the
‘‘dominant tolerance,’’ known to be mediated by Foxp3+ Treg
cells in this system (Quezada et al., 2005), is in part mediated
through the persistent effects of DCs. Furthermore, the break-
down in tolerance with the depletion of DCs is consistent with
the recently recognized function of DCs inmaintaining peripheral
self tolerance (Lutz and Kurts, 2009). From previous studies, it
was shown that under inflammatory conditions, MC-derived
Figure 7. MC-Derived GM-CSF Is Required for
Graft Tolerance by Increasing Longevity of Tolero-
genic Graft-Derived DCs
(A) KitW-sh mice were locally reconstituted with either WT
or Csf2/ BMMCs. Mice were tolerized and grafted
8–10 weeks later and monitored for graft rejection.
(B and C) KitW-shmice were reconstituted and grafted as in
(A). At 10 days postgrafting, FITC was applied to the graft
to label the graft-derived DCs. After 12 hr, dLNs were
collected and stained with MitoTracker so that the viability
of the graft-derived DC could be evaluated. Shown are
a representative histogram (B) and accompanying quanti-
fication (C). Data were pooled from two independent
experiments (n = 10/group, mean ± SEM).
Immunity
Mast Cells Condition Tolerogenic Dendritic CellsTNFa was required for optimal DC migration (Shelburne et al.,
2009; Suto et al., 2006), and therefore, we considered the role
of TNFa in MC-induced DC migration in tolerance. By FITC
painting, the data presented clearly show that the regional
blockade of TNFa prohibited DC migration and facilitated a
breakdown in graft tolerance. Although we did not specifically
establish that TNFa production from MCs was involved in graft
survival or in controlling DC migration, in the absence of MC,
graft tolerance could not be established and DC migration was
ablated. Therefore, we presume that MC-derived TNFa is re-
sponsible for DC migration both in tolerance and as previously
established in inflammation (Shelburne et al., 2009; Suto et al.,
2006).
In addition to the need for DC migration, graft-derived DCs
from tolerant allografts accumulated in higher numbers in the
regional LN when compared to those derived from syngeneic
or rejecting allografts. After excluding many possible reasons
for the observed increase, we concluded that the most likely
explanation for this phenomenon was increased DC survival.
Recently, it was shown that an increase of GM-CSF in the uterine
endometrium at coitus is required for suppression of T cell
responses needed to protect the fetus from being rejected by
the mother (Moldenhauer et al., 2010). Maternal tolerance is
similar to the acquired tolerance to an allograft. This comparison
was further strengthened by our finding that the concentration of
GM-CSF in grafts of pretolerized mice was markedly increased
as measured by Luminex and ELISA. Therefore, GM-CSF was
a potential target important for the induction and maintenance
of acquired immune tolerance.
Production of GM-CSF by MC in tolerant allografts appears to
play a pivotal role in sustaining graft survival. Besides ELISA,
histological analysis also indicated heightened levels of GM-
CSF in tolerant allografts, but failed to show cell-specific associ-
ation. This might be due to the nature of GM-CSF that belongs to
the group of heparin-binding growth factors. Besides directlyImmunity 35, 55binding of GM-CSF to the GM-CSF receptor, it
can also be presented by binding to heparan-
containing proteoglycans present on other cells,
such as skin fibroblasts and stromal cells. This
modulates the biological activity of GM-CSF
(Alvarez-Silva and Borojevic, 1996; Modrowski
et al., 1998) and explains the observed staining
pattern of GM-CSF in our histological studies.
Presentation of high levels of GM-CSF by skinfibroblast has shown to inhibit activation and proliferation of
bone marrow-derived progenitor cells, whereas low levels of
presentation induced activation and proliferation (Carvalho
et al., 2000). Thus, the observed low levels of GM-CSF in reject-
ing allografts could potentially activate DCs but will haveminimal
influence on their survival. In contrast, the high levels of GM-CSF
in tolerized mice could potentially suppress maturation of the
graft-derived DCs, rendering them more tolerogenic and addi-
tionally increasing their longevity. Because the histology proved
inconclusive with regard to MCs being a possible source of GM-
CSF, we resorted to analysis of in vitro-cultured BMMCs. After
activation of these MCs, we detected intracellular GM-CSF ac-
companied by copious amounts of GM-CSF in the culture super-
natant. Furthermore, enhanced survival was observed when
freshly isolated splenic DCs were cultured in this supernatant.
Studies were undertaken to evaluate the molecular basis for
the enhanced survival of DCs from tolerant allografts. These
studies looked at the expression of molecules involved in apo-
ptosis. There are three main pathways that induce apoptosis,
which are intertwined (Chen et al., 2007; Faderl et al., 2003). First,
granzyme B (Gzb)-mediated killing by Treg and CD8 Teff cells
has been shown to reduce the number of DCs in the tumor
dLN and suppress immune responses (Cao et al., 2007). Gzb-
mediated killing can be evaded by upregulation of the serpin
protease inhibitor Spi6 (Medema et al., 2001). Given that we
had previously shown that skin graft tolerance is maintained by
Gzb+ Treg cells (Gondek et al., 2008), it was not surprising to
see an upregulation of Spi6 in the graft-derived DC. Second,
activation of the caspase pathwaywas not affected in ourmodel,
even though in vitro studies showed upregulation of the sup-
pressors Ciap1 and C-FLIP due to the presence of GM-CSF
(Faderl et al., 2003; Leverkus et al., 2000). Third, the nutrient
deprivation pathway was the most strikingly affected. In concor-
dance with in vitro-cultured DCs, GM-CSF induced the expres-
sion of both the antiapoptotic molecules Bcl2 and BclXL, in0–561, October 28, 2011 ª2011 Elsevier Inc. 559
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cule BAD. This would suggest that in the transplant there might
a local depletion of one or more of the essential amino acids,
which has been shown to be an important mechanism to induce
and maintain tolerance (Cobbold et al., 2009).
To further address the importance of GM-CSF in allograft
tolerance, we performed a series of experiments manipulating
GM-CSF in vivo. Removing GM-CSF by either blocking anti-
bodies or by using Csf2/ mice in pretolerized mice induced
rejection whereas introducing GM-CSF to untreated mice with
an allograft could delay rejection. This confirms that GM-CSF
is required for the maintenance of tolerance. Additionally, GM-
CSF has a profound impact on one of the major producers of
GM-CSF outside the bone marrow, the MC. The presence of
GM-CSF has shown to downregulate cKit and FcεRI and levels
of tryptase and histamine in in vitro-cultured MCs (Welker
et al., 2001). This would suggest that the MCs in the graft are
less sensitive to degranulation due to the high concentration of
local GM-CSF. This further contributes to maintenance of toler-
ance because previously we showed that degranulation is detri-
mental for graft survival (de Vries et al., 2009).
In 2006, we showed that MCs are required for the induction
and maintenance of graft tolerance (Lu et al., 2006). This study
provides a mechanistic and molecular explanation for this re-
quirement by functionally linking MCs to DCs and showing




C57Bl/6 (Ly5.1+ or Ly5.2+), CB6F1, C57Bl/6-TCRb5.2, C57Bl/6J.Kit
W-sh
(Jackson Laboratory, Bar Harbor, Maine, USA) mice were used. The Ly5.2+
mice were bred onto OTII CD4-Tg mice. B6.Itgax-DTR mice were a kind gift
of J.R. Conejo-Garcia (Dartmouth Medical School, Lebanon, NH, USA).
B6.Csf2/ mice were provided by J.A. Whitsett (University of Cincinnati
College of Medicine, Cincinnati, Ohio, USA). All animal protocols were ap-
proved by the Institutional Animal Care and Use Committee of Dartmouth
College.
Skin Graft Model
Skin grafting was performed in accordance with the procedure described
previously (Quezada et al., 2005).
In Vivo Tracking of DC Migration
For migration studies, 8 ml of 5 mg/ml FITC-paint was applied directly onto the
preshaved graft, whereas Dextran-A647 and DQ-OVA were injected subcuta-
neously (s.c.) in the graft. DC migration from the graft was blocked by local
injection of 50 ml of sTNFR-Ig (20 mg/ml). For DC depletion, Itgax-DTR mice
were locally treated with 10 ng of DT.
Cytokine Analysis
Day 10 grafts were incubated in HBSS (500mg graft tissue/ml) for 1 hr at 37C.
Cytokines in the supernatant were analyzed by multiplex analysis and recon-
firmed by ELISA. GM-CSF production byMCs in vitro wasmeasured by ELISA.
Immunohistochemistry
dLN were collected at 18 hr after FITC painting of day 10 grafts and compared
to graft dLN of day 11 grafts without FITC painting. Slides were stained with
CD11c and Hoechst. Skin sections were stained with cKit, CD11c, and GM-
CSF. For cytospins, week 6 BMMCs were activated with 1 mg/ml of DNP-IgE
for 12 hr followed by 2 hr in the presence of monensin. Cells were stained
with cKit, FcεRI, GM-CSF, and Hoechst as nuclear stain. GM-CSF staining560 Immunity 35, 550–561, October 28, 2011 ª2011 Elsevier Inc.controls included isotype (Rat IgG2b-FITC) and preincubation with unlabelled
GM-CSF. All slides were recorded by confocal microscopy (LSM 510Meta,
Zeiss).
Dendritic Cell Phenotyping and Functionality
Day 10 graft derived FITC+ DCs 12h post-FITC painting were analyzed for six
major subsets known to be present in skin dLNs. Survival potential of DCs
subsets in response to GM-CSF was assessed in vitro over time. For function-
ality studies, dLN were collected after FITC painting and Ly5.1+CD11c+
MHCIIhighFITC+ DCs were sorted (FACSAria) yielding purities of over 98%.
DCs were pulsed with ISQ (1 hr, 37C), washed, and plated at different ratios
with 40.103 naive CFSE-labeled Ly5.2+OT-II T cells and analyzed for CFSE dye
dilution on day 4. For both dominant suppression and antigen-specific sup-
pression, DCs from whole LN were sorted. For antigen-specific suppression
in vivo, mice were injected with 50 ml OVA-Alum (1 mg/ml) either in the graft
or the front footpad prior to DC sorting.
In Vitro Analysis of MC-Induced DC Survival
WT andCsf2/BMMCswere cultured for 3 weeks with 20 ng/ml recombinant
IL-3 and subsequently for 3–5 weeks with rIL-3 and 50 ng/ml rSCF. MCs were
plated at a concentration of 1.106/ml in the presence or absence of 1 mg/ml
DNP-IgE or 10 ng/ml rIL-33 for activation. Purified splenic DCs were plated
in the different MC-conditioned media at 40.103/well. As positive control,
DCs were cultured with 20 ng/ml rGM-CSF whereas for negative control,
this was omitted. DCs were analyzed for cell death by MitoTracker deep red
and trypan blue.
In Vivo Analysis of DC Survival
Grafts of syngeneic, rejecting, and tolerized mice were FITC painted and dLNs
were analyzed at 3, 6, 9, 12, 15, 24, 48, and 72 hr after FITC painting for the
presence of graft-derived DC by flow cytometry either in the presence or
absence of sTNFR-Ig. Additionally FITC+ DCs were analyzed at 12 hr post-
FITC painting for viability by MitoTracker staining.
RT-PCR on Graft-Derived DCs
FITC+ graft-derived DCs were purified at day 10 postgrafting and 12 hr
after FITC painting. DCs were sorted directly into lysis buffer (Ambion). RNA
was purified and amplified before analysis by RT-PCR (MessageAmp II
aRNA Amplification kit, Applied Biosciences). Purity was evaluated after
each step.
In Vivo Studies on the Role of MC-Derived GMCSF in DC Survival
Micewere grafted with either syngeneic or allogeneic grafts without prior treat-
ment. At day 1, 3, 5, and 7 mice received a local intragraft injection of 50 ml
recombinant GM-CSF (800 ng/ml). Graft rejection was followed for 30 days
after grafting. Conversely, tolerized animals and syngeneic controls received
50 ml aGMSCF (10 mg/ml) at the same days so that GM-CSF was blocked
locally. Additionally, Csf2/ mice were grafted with syngeneic or allogeneic
skins (rejecting and tolerant). To specifically address the role of MCs, we
reconstituted KitW-sh mice locally with 6–8 weeks of cultured WT or Csf2/
BMMCs (Lu, et al., 2006). After 8 weeks, mice were tolerized and grafted. After
each experiment, mice were analyzed for the presence of cKit+FcεRIhigh cells
so that MC reconstitution could be confirmed. Mice that failed to reconstitute
were excluded from the studies.
Statistics
All statistics have been calculated with the Prism 4.03 software package
(GraphPad Software). Luminex data are shown as mean ± SD, whereas other
data are expressed as mean ± SEM. Statistical significance was calculated for
a 95% confidence interval (p < 0.05). Statistical methods are further specified
in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.immuni.2011.09.012.
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